Quick Answer
Damora Therapeutics, Inc. reported R&D Expense of $26.88 million for fiscal year 2025.
Damora Therapeutics, Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $26.88M | +320.1% |
| 2024 | $6.40M | -73.1% |
| 2023 | $23.77M | -50.7% |
| 2022 | $48.21M | +25.2% |
| 2021 | $38.49M | +56.3% |
| 2020 | $24.63M | +24.8% |
| 2019 | $19.74M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $1.42M | +29.6% | -3.3% |
| June 30, 2025 | $1.47M | -20.1% | +116.1% |
| March 31, 2025 | $678.0K | -72.5% | -38.0% |
| September 30, 2024 | $1.09M | -57.2% | -40.4% |
| June 30, 2024 | $1.83M | -77.3% | -25.5% |
| March 31, 2024 | $2.46M | -76.2% | -3.4% |
| September 30, 2023 | $2.55M | -75.7% | -68.5% |
| June 30, 2023 | $8.09M | -41.0% | -21.9% |
- Damora Therapeutics, Inc. showed an increase of +320.1% in R&D Expense compared to the prior fiscal year.
- Over the 2019–2025 period, Damora Therapeutics, Inc.’s r&d expense has grown by 36.2% (from $19.74 million to $26.88 million).
- The most recent figure is from Damora Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 19, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: